Alleviation of symptoms associated with allergic rhinitis and urticaria in adults, adolescents aged 12 years and older.
Composition:
1 tabl disintegrating in the mouth contains 5 mg of desloratadine.
Action:
Desloratadine is a sedative, long-acting histamine antagonist with selective antagonistic activity towards peripheral H-receptors1. Antiallergic properties of desloratadine include inhibiting the release of cytokines inducing an inflammatory response (i.e., IL-4, IL-6, IL-8 and IL-13) from human mast cells and basophils, as well as inhibiting the expression of P-selectin on the surface of endothelial cells. In patients with allergic rhinitis, desloratadine is effective in relieving symptoms such as sneezing, pruritus, nasal discharge, as well as itching, tearing and redness of the eyes and pruritis. In patients with urticaria, it reduces the number and size of urticarial lesions and soothes pruritus. Desloratadine practically does not penetrate to o.u.n., thanks to which it does not exert a calming effect, does not cause drowsiness or does not affect psychomotor activity. Desloratadine is rapidly absorbed from the gastrointestinal tract (about 30 min), reaching Cmax after about 3 h. Plasma protein binding is 83-87%. T0,5 is 27 hours.
Contraindications:
Hypersensitivity to the active substance, loratadine or to any of the excipients.
Precautions:
Use with caution in patients with severe renal impairment. The efficacy and safety of the medicine in children <12 years have not been established. There is insufficient data on the efficacy of desloratadine in adolescents aged 12 to 17 years.
Pregnancy and lactation:
It is not recommended during pregnancy (no data on the safety of use). Desloratadine was found in the body of newborns / breast-fed children by women who took the medicine. The effect of desloratadine on the newborn / infant organism is unknown. A decision should be made whether to discontinue breast-feeding or discontinue the treatment taking into account the benefits of breastfeeding for the child and the benefits of treatment for the mother.
Orally. Adults and adolescents ≥12 years: 5 mg once a day. The safety and efficacy of the preparation in the form of orally disintegrating in children under 12 years of age (no data available). There is insufficient data on the effectiveness of desloratadine in adolescents aged 12 to 17 years. In periodic allergic rhinitis (symptoms occur less than 4 days in a week or less than 4 weeks), treatment should be discontinued after the symptoms have resolved and resumed when they recur. In chronic allergic rhinitis (symptoms occur for 4 days in a week or more and for more than 4 weeks) you can continue treatment during the period of exposure to the allergen.Way of giving. The drug can be taken regardless of meals. Table. submissive. the verdict in oral language is placed in the oral cavity, where it undergoes immediate disintegration; no water or other liquid is needed to swallow the dose; The dose should be taken immediately after opening the blister.
(C)
